series-b
Stage
2018
Founded
4
Investors
About
Aurealis Therapeutics develops scalable multi-target cell and gene therapies that modulate tissue microenvironments to treat chronic wounds, cancers, and inflammatory diseases, with clinical-stage programs including AUP-16 for diabetic foot ulcers and AUP-55 for cancer.
Explore Aurealis Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.